ASTRANA HEALTH INC (ASTH) Fundamental Analysis & Valuation

NASDAQ:ASTH • US03763A2078

23.375 USD
-1.34 (-5.44%)
Last: Mar 10, 2026, 01:39 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ASTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

ASTH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. While ASTH is still in line with the averages on profitability rating, there are concerns on its financial health. ASTH is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. ASTH Profitability Analysis

1.1 Basic Checks

  • ASTH had positive earnings in the past year.
  • In the past year ASTH had a positive cash flow from operations.
  • ASTH had positive earnings in 4 of the past 5 years.
  • ASTH had a positive operating cash flow in 4 of the past 5 years.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • With a Return On Assets value of 0.43%, ASTH perfoms like the industry average, outperforming 49.51% of the companies in the same industry.
  • ASTH's Return On Equity of 1.23% is in line compared to the rest of the industry. ASTH outperforms 55.45% of its industry peers.
  • The Return On Invested Capital of ASTH (2.95%) is comparable to the rest of the industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ASTH is in line with the industry average of 8.98%.
  • The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROIC 2.95%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • With a Profit Margin value of 0.33%, ASTH perfoms like the industry average, outperforming 49.51% of the companies in the same industry.
  • ASTH's Profit Margin has declined in the last couple of years.
  • ASTH's Operating Margin of 2.59% is in line compared to the rest of the industry. ASTH outperforms 51.49% of its industry peers.
  • In the last couple of years the Operating Margin of ASTH has declined.
  • Looking at the Gross Margin, with a value of 10.25%, ASTH is doing worse than 73.27% of the companies in the same industry.
  • ASTH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ASTH Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
  • There is no outstanding debt for ASTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ASTH has an Altman-Z score of 2.24. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ASTH has a Altman-Z score of 2.24. This is comparable to the rest of the industry: ASTH outperforms 54.46% of its industry peers.
  • ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 10.83, ASTH is in line with its industry, outperforming 43.56% of the companies in the same industry.
  • ASTH has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
  • ASTH has a worse Debt to Equity ratio (1.29) than 65.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Altman-Z 2.24
ROIC/WACC0.36
WACC8.12%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • ASTH has a Current Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
  • ASTH has a Current ratio (1.40) which is in line with its industry peers.
  • ASTH has a Quick Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.40, ASTH is in line with its industry, outperforming 59.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ASTH Growth Analysis

3.1 Past

  • ASTH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.12%.
  • The Earnings Per Share has been decreasing by -6.01% on average over the past years.
EPS 1Y (TTM)-1.12%
EPS 3Y-6.01%
EPS 5YN/A
EPS Q2Q%460%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%42.89%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.56% on average over the next years. This is a very strong growth
  • ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.59% yearly.
EPS Next Y43.41%
EPS Next 2Y47.38%
EPS Next 3Y51.33%
EPS Next 5Y35.56%
Revenue Next Year25.22%
Revenue Next 2Y17.78%
Revenue Next 3Y10.21%
Revenue Next 5Y9.59%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

5

4. ASTH Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 26.56, the valuation of ASTH can be described as expensive.
  • ASTH's Price/Earnings is on the same level as the industry average.
  • The average S&P500 Price/Earnings ratio is at 26.45. ASTH is around the same levels.
  • With a Price/Forward Earnings ratio of 18.52, ASTH is valued on the expensive side.
  • ASTH's Price/Forward Earnings is on the same level as the industry average.
  • ASTH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.65, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.56
Fwd PE 18.52
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASTH.
  • 77.23% of the companies in the same industry are more expensive than ASTH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.09
EV/EBITDA 16.21
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ASTH's earnings are expected to grow with 51.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y47.38%
EPS Next 3Y51.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASTH Dividend Analysis

5.1 Amount

  • ASTH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTH Fundamentals: All Metrics, Ratios and Statistics

ASTRANA HEALTH INC

NASDAQ:ASTH (3/10/2026, 1:39:03 PM)

23.375

-1.34 (-5.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners59.72%
Inst Owner ChangeN/A
Ins Owners9.87%
Ins Owner Change0.99%
Market Cap1.17B
Revenue(TTM)N/A
Net Income(TTM)9.54M
Analysts84.71
Price Target36.38 (55.64%)
Short Float %7.27%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.13%
PT rev (3m)-11.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.36%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-16.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE 26.56
Fwd PE 18.52
P/S 0.4
P/FCF 12.09
P/OCF 11.01
P/B 1.51
P/tB N/A
EV/EBITDA 16.21
EPS(TTM)0.88
EY3.76%
EPS(NY)1.26
Fwd EY5.4%
FCF(TTM)1.93
FCFY8.27%
OCF(TTM)2.12
OCFY9.09%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)0.61
PEG (5Y)N/A
Graham Number17.5
Profitability
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROCE 4.68%
ROIC 2.95%
ROICexc 4.15%
ROICexgc N/A
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
FCFM 3.35%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Debt/EBITDA 8.9
Cap/Depr 25.55%
Cap/Sales 0.33%
Interest Coverage 2.01
Cash Conversion 94.59%
Profit Quality 1016.69%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.24
F-Score3
WACC8.12%
ROIC/WACC0.36
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.12%
EPS 3Y-6.01%
EPS 5YN/A
EPS Q2Q%460%
EPS Next Y43.41%
EPS Next 2Y47.38%
EPS Next 3Y51.33%
EPS Next 5Y35.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%42.89%
Revenue Next Year25.22%
Revenue Next 2Y17.78%
Revenue Next 3Y10.21%
Revenue Next 5Y9.59%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y45.21%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A

ASTRANA HEALTH INC / ASTH FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 5 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 26.56 and the Price/Book (PB) ratio is 1.51.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.